Evaluation of amphetamine-induced hyperlocomotion and catalepsy following long-acting risperidone administration in rats

European Journal of Pharmacology

Volumn 620, Issue 1-3, 2009, Pages 36-41

  Marchese, Giorgio ^a,b   Casu, Gianluca ^b   Casti, Paola ^b   Spada, Gabriele Pinna ^b   Pani, Luca ^a,b  

^a CNR   (Italy)

^b SARDEGNA RICERCHE   (Italy)

Author keywords

Amphetamine; Antipsychotic; Catalepsy; Long acting; Risperidone

Indexed keywords

AMPHETAMINE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; EVENING DOSAGE; EXTRAPYRAMIDAL SYMPTOM; LOCOMOTION; MALE; MORNING DOSAGE; MOTOR DYSFUNCTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMPHETAMINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; CATALEPSY; CHEMISTRY, PHARMACEUTICAL; HYPERKINESIS; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RISPERIDONE; TIME FACTORS;

EID: 70349094451     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.024     Document Type: Article

References (19)

1. Bai Y.M., Chen T.T., Wu B., Hung C.H., Lin W.K., Hu T.M., Lin C.Y., and Chou P. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 39 (2006) 135-141
2. Bai Y.M., Ting C.T., Chen J.Y., Chang W.H., Wu B., Hung C.H., and Kuo L.W. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 68 (2007) 1218-1225
3. Eerdekens M., Van Hove I., Remmerie B., and Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr. Res. 70 (2004) 91-100
4. Ereshefsky L., and Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs Respir. Des. 6 (2005) 129-137
5. Ereshefsky L., and Mascarenas C.A. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry 64 (2003) 18-23
6. Fleischhacker W.W., Eerdekens M., Karcher K., Remington G., Llorca P.M., Chrzanowski W., Martin S., and Gefvert O. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 64 (2003) 1250-1257
7. Fleischhacker W.W., Rabinowitz J., Kemmler G., Eerdekens M., and Mehnert A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br. J. Psychiatry 187 (2005) 131-136
8. Gefvert O., Eriksson B., Persson P., Helldin L., Bjorner A., Mannaert E., Remmerie B., Eerdekens M., and Nyberg S. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 27-36
9. Gharabawi G.M., Gearhart N.C., Lasser R.A., Mahmoud R.A., Zhu Y., Mannaert E., Naessens I., Bossie C.A., Kujawa M., and Simpson G.M. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann. Gen. Psychiatry 6 (2007) 3
10. Kane J.M., Eerdekens M., Lindenmayer J.P., Keith S.J., Lesem M., and Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 160 (2003) 1125-1132
11. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry 157 (2000) 514-520
12. Kapur S., VanderSpek S.C., Brownlee B.A., and Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J. Pharmacol. Exp. Ther. 305 (2003) 625-631
13. Mannaert E., Vermeulen A., Remmerie B., Bouhours P., and Levron J.C. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale 31 (2005) 609-615
14. Marinis T.D., Saleem P.T., Glue P., Arnoldussen W.J., Teijeiro R., Lex A., Latif M.A., and Medori R. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 40 (2007) 257-263
15. Medori R., Mannaert E., and Grunder G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur. Neuropsychopharmacol. 16 (2006) 233-240
16. 2 receptor occupancy for long-acting injectable risperidone. Am. J. Psychiatry 163 (2006) 396-401
17. Schmauss M., Sacchetti E., Kahn J.P., and Medori R. Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int. Clin. Psychopharmacol. 22 (2007) 85-92
18. Simpson G.M., Mahmoud R.A., Lasser R.A., Kujawa M., Bossie C.A., Turkoz I., Rodriguez S., and Gharabawi G.M. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 67 (2006) 1194-1203
19. 2 receptor occupancy for the management of schizophrenia. J. Clin. Psychiatry 69 (2008) 1281-1286